Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition used for treating diabetes mellitus, and application thereof

A composition and technology for diabetes, applied in the direction of gene therapy, drug combination, metabolic diseases, etc., can solve the problem of the insignificant effect of type I diabetes, and achieve the effect of promoting blocking of autoimmunity, simple method and high cure rate

Active Publication Date: 2012-03-28
KUNMING INNOGEN PHARM TECH CO LTD +2
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Very effective in type 2 diabetes but less effective in type 1 diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition used for treating diabetes mellitus, and application thereof
  • Composition used for treating diabetes mellitus, and application thereof
  • Composition used for treating diabetes mellitus, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] Further illustrate content of the present invention in conjunction with accompanying drawing:

[0030] Such as figure 1 As shown, the diabetic model induced by MLDS (i.p.40mg / kg BW, for 4 consecutive days) in mice can be blocked by daily injection of GABA treatment. The rodent model of MLDS is a commonly used model of type 1 diabetes. In the MLDS model, insulin deficiency is caused by the destruction of islet β-cells by STZ. To some extent, T-cell mediated [beta]-cell inflammation (insulitis) was also seen in the MLDS-induced diabetic hyperglycemia model. However, a single high dose (such as 200-250mg / kg BW) of STZ may not cause insulitis, because the islet β-cells will be destroyed quickly. So, MLDS is a model of β-cell injury, with some insulitis, but not an ideal model of autoimmune disease. Daily intraperitoneal administration of GABA (2 mg / mouse) prevented the development of diabetic hyperglycemia in MLDS CD1 mice ( figure 1 A). Under the current experimental ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition used for treating diabetes mellitus. The composition comprises an effective dosage of a composition of a compound gamma-aminobutyric acid (GABA) and a composition GABAergic thereof, or a composition of GABA and increatin. When the composition is specifically applied in-vivo in a type-I diabetes subject, with the application of GABA, beta-cell apoptosis can be inhibited, beta-cell regeneration can be promoted, autoimmune responses aiming at pancreatic islet beta-cells can be inhibited, and a substantial diabetes mellitus inversion efficacy can be achieved. The increatin described in the invention is GLP-1 or exendin-4. The effect of GLP-1 / exendin-4 upon type-I diabetes is limited. However, GLP-1 / exendin-4 and GABA provide a synergistic effect, and the efficacy of GABA is substantially improved. According to the invention, GABA and GLP-1 / exendin-4 are simultaneously applied in-vivo in a subject, and enhanced biological effects are obtained. When GABA and GLP-1 / exendin-4 are simultaneously applied in a type-I diabetes individual, hyperglycemia of diabetes mellitus can be completely inverted.

Description

technical field [0001] The present invention relates to a kind of composition and application method thereof for preventing and treating diabetes, more specifically about compound gamma-aminobutyric acid, gamma-aminobutyric acid molecule (GABAergic) used alone or in combination with Combined use of glucagon-like peptide-1 (GLP-1), incretin and its analogs (such as exendin-4) to promote proliferation of islet β-cells, inhibit islet inflammatory response, and reduce islet β - A composition for treating diabetes and its application, which can autoimmune cells and enhance the function of regulating T-cells, and can prevent and treat diabetes patients. Background technique [0002] Diabetes is one of the main causes of human death. Type I diabetes is a major type of diabetes, characterized by early onset age and autoimmune destruction of islet β-cells, resulting in insufficient insulin secretion and the need to rely on exogenous insulin therapy. Apoptosis is the main form of is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197A61K38/26A61K38/22A61K48/00A61P3/10
CPCC07K14/605A61K31/7088A61K38/2278A61K31/195A61K31/197A61K38/26A61K45/06A61K2300/00A61P3/10
Inventor 王庆华耐普顿·索尔塔尼
Owner KUNMING INNOGEN PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com